表紙
市場調查報告書
商品編碼
1056868

生技藥品CDMO的全球市場 (2022年∼2026年)

Global Biologics CDMO Market 2022-2026

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球生技藥品CDMO的市場規模在2022年∼2026年間,預測將成長到86億5,000萬美元,在預測期間內預計將以12.20%的年複合成長率成長。

市場成長的主要因素有新興市場具有成本效益的資源利用和強大的生物製藥研發渠道。

本報告提供全球生技藥品CDMO市場相關調查分析,提供整體分析,市場規模與預測,趨勢,成長促進因素,課題,加上約25公司的供應商作為對象的供應商分析等資訊。

目錄

摘要整理

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模 (2021年)
  • 市場預測:2021年∼2026年的預測

波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

各類型的市場區隔

  • 市場區隔
  • 各類型的比較
  • 哺乳類 - 市場規模與預測(2021年∼2026年)
  • 微生物 - 市場規模與預測(2021年∼2026年)
  • 細胞治療服務 - 市場規模與預測(2021年∼2026年)
  • 各類型的市場機會

各地區的形勢

  • 各地區的市場區隔
  • 各地區的比較
  • 北美 - 市場規模與預測(2021年∼2026年)
  • 歐洲 - 市場規模與預測(2021年∼2026年)
  • 亞洲 - 市場規模與預測(2021年∼2026年)
  • 其他地區 - 市場規模與預測(2021年∼2026年)
  • 主要國家
  • 各地區形勢的市場機會
  • 推動市場要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 混亂狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AGC Biologics
  • Binex Co. Ltd.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Fujifilm Diosynth Biotechnologies USA Inc.
  • JRS PHARMA GmbH and Co. KG
  • Lonza Group Ltd.
  • Rentschler Biopharma SE
  • Samsung BioLogics Co. Ltd.
  • WuXi Biologics(Cayman)Inc.

附錄

目錄
Product Code: IRTNTR72001

Technavio has been monitoring the biologics CDMO market and it is poised to grow by $ 8.65 bn during 2022-2026, progressing at a CAGR of 12.20% during the forecast period. Our report on the biologics CDMO market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the availability of cost-efficient resources in emerging markets and strong research and development pipeline of biologics therapeutics. In addition, the availability of cost-efficient resources in emerging markets is anticipated to boost the growth of the market as well.

The biologics CDMO market analysis includes the type segment and geographic landscape.

Technavio's biologics CDMO market is segmented as below:

By Type

  • Mammalian
  • Microbial
  • Cell therapy services

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing need to focus on core competenciesas one of the prime reasons driving the biologics CDMO market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on biologics CDMO market covers the following areas:

  • Biologics CDMO market sizing
  • Biologics CDMO market forecast
  • Biologics CDMO market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biologics CDMO market vendors that include AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., Fujifilm Diosynth Biotechnologies USA Inc., JRS PHARMA GmbH and Co. KG, Lonza Group Ltd., Rentschler Biopharma SE, Samsung BioLogics Co. Ltd., and WuXi Biologics (Cayman) Inc. Also, the biologics CDMO market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2021
    • Market outlook: Forecast for 2021 - 2026
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Type
    • Market segments
    • Comparison by Type
    • Mammalian - Market size and forecast 2021-2026
    • Microbial - Market size and forecast 2021-2026
    • Cell therapy services - Market size and forecast 2021-2026
    • Market opportunity by Type
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2021-2026
    • Europe - Market size and forecast 2021-2026
    • Asia - Market size and forecast 2021-2026
    • ROW - Market size and forecast 2021-2026
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • AGC Biologics
    • Binex Co. Ltd.
    • Boehringer Ingelheim International GmbH
    • Catalent Inc.
    • Fujifilm Diosynth Biotechnologies USA Inc.
    • JRS PHARMA GmbH and Co. KG
    • Lonza Group Ltd.
    • Rentschler Biopharma SE
    • Samsung BioLogics Co. Ltd.
    • WuXi Biologics (Cayman) Inc.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2021 - 2026 ($ million)
  • 13: Global market: Year-over-year growth 2021 - 2026 (%)
  • 14: Five forces analysis 2021 & 2026
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2021
  • 21: Type - Market share 2021-2026 (%)
  • 22: Comparison by Type
  • 23: Mammalian - Market size and forecast 2021-2026 ($ million)
  • 24: Mammalian - Year-over-year growth 2021-2026 (%)
  • 25: Microbial - Market size and forecast 2021-2026 ($ million)
  • 26: Microbial - Year-over-year growth 2021-2026 (%)
  • 27: Cell therapy services - Market size and forecast 2021-2026 ($ million)
  • 28: Cell therapy services - Year-over-year growth 2021-2026 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share By Geographical Landscape 2021-2026 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2021-2026 ($ million)
  • 34: North America - Year-over-year growth 2021-2026 (%)
  • 35: Europe - Market size and forecast 2021-2026 ($ million)
  • 36: Europe - Year-over-year growth 2021-2026 (%)
  • 37: Asia - Market size and forecast 2021-2026 ($ million)
  • 38: Asia - Year-over-year growth 2021-2026 (%)
  • 39: ROW - Market size and forecast 2021-2026 ($ million)
  • 40: ROW - Year-over-year growth 2021-2026 (%)
  • 41: Key leading countries
  • 42: Market opportunity By Geographical Landscape ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AGC Biologics - Overview
  • 50: AGC Biologics - Product and service
  • 51: AGC Biologics - Key offerings
  • 52: AGC Biologics - Key customers
  • 53: AGC Biologics - Segment focus
  • 54: Binex Co. Ltd. - Overview
  • 55: Binex Co. Ltd. - Product and service
  • 56: Binex Co. Ltd. - Key offerings
  • 57: Binex Co. Ltd. - Key customers
  • 58: Binex Co. Ltd. - Segment focus
  • 59: Boehringer Ingelheim International GmbH - Overview
  • 60: Boehringer Ingelheim International GmbH - Business segments
  • 61: Boehringer Ingelheim International GmbH - Key offerings
  • 62: Boehringer Ingelheim International GmbH - Key customers
  • 63: Boehringer Ingelheim International GmbH - Segment focus
  • 64: Catalent Inc. - Overview
  • 65: Catalent Inc. - Business segments
  • 66: Catalent Inc. - Key offerings
  • 67: Catalent Inc. - Key customers
  • 68: Catalent Inc. - Segment focus
  • 69: Fujifilm Diosynth Biotechnologies USA Inc. - Overview
  • 70: Fujifilm Diosynth Biotechnologies USA Inc. - Product and service
  • 71: Fujifilm Diosynth Biotechnologies USA Inc. - Key offerings
  • 72: Fujifilm Diosynth Biotechnologies USA Inc. - Key customers
  • 73: Fujifilm Diosynth Biotechnologies USA Inc. - Segment focus
  • 74: JRS PHARMA GmbH and Co. KG - Overview
  • 75: JRS PHARMA GmbH and Co. KG - Product and service
  • 76: JRS PHARMA GmbH and Co. KG - Key offerings
  • 77: JRS PHARMA GmbH and Co. KG - Key customers
  • 78: JRS PHARMA GmbH and Co. KG - Segment focus
  • 79: Lonza Group Ltd. - Overview
  • 80: Lonza Group Ltd. - Business segments
  • 81: Lonza Group Ltd. - Key offerings
  • 82: Lonza Group Ltd. - Key customers
  • 83: Lonza Group Ltd. - Segment focus
  • 84: Rentschler Biopharma SE - Overview
  • 85: Rentschler Biopharma SE - Product and service
  • 86: Rentschler Biopharma SE - Key offerings
  • 87: Rentschler Biopharma SE - Key customers
  • 88: Rentschler Biopharma SE - Segment focus
  • 89: Samsung BioLogics Co. Ltd. - Overview
  • 90: Samsung BioLogics Co. Ltd. - Business segments
  • 91: Samsung BioLogics Co. Ltd. - Key offerings
  • 92: Samsung BioLogics Co. Ltd. - Key customers
  • 93: Samsung BioLogics Co. Ltd. - Segment focus
  • 94: WuXi Biologics (Cayman) Inc. - Overview
  • 95: WuXi Biologics (Cayman) Inc. - Business segments
  • 96: WuXi Biologics (Cayman) Inc. - Key offerings
  • 97: WuXi Biologics (Cayman) Inc. - Key customers
  • 98: WuXi Biologics (Cayman) Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations